6 news items
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
SYRS
14 May 24
not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
SYRS
9 Apr 24
or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SYRS
2 Apr 24
with commencing employment with Syros. This RSU was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
SYRS
27 Mar 24
not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
SYRS
25 Mar 24
these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking
u301bh2calaa5guj2x8j1o5zqvt4ocxfoefyxxnta5hwj8lol2vna49soz
ALKS
INMD
KPRX
11 Mar 24
may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
- Prev
- 1
- Next